Paris- Fresh lockdowns and curfews have been imposed on tens of millions of people from India to Argentina as COVID-19 infections surged again and vaccine rollouts were hampered by shortages and fears of side effects.
In India, the worst-hit state of Maharashtra was running out of vaccines as the health system buckled under the weight of the contagion, which has killed 2.9 million people worldwide.
Having let its guard down with mass religious festivals, political rallies and spectators at cricket matches, the world’s second-most populous nation has added more than a million new infections since late March.
Every weekend, from Saturday until the end of April, Maharashtra’s 125 million people will be confined to their homes unless travelling or shopping for food or medicine.
Stay-at-home orders were also set to come into force for the eight million inhabitants of Bogota, as the Colombian capital battled a third wave of infections, adding to curfews already covering seven million across four other big cities.
Argentina entered a night-time curfew on Friday, running from midnight to 6am every day until April 30.
It will be in force in the country’s highest-risk areas, mainly urban centres, where bars and restaurants will close at 11pm.
Argentina and Colombia have recorded about 2.5 million coronavirus cases, numbers surpassed only by Brazil in the region.
All of France is subject to restrictions of some form, while the German government’s attempts to curb movement and commerce have been stymied by several states refusing to go along with the proposals.
Now Berlin is changing the rules to centralise power, adjustments likely to usher in night-time curfews and some school closures in especially hard-hit areas.
But some countries were in the process of opening up.
Italy was set to end lockdowns from next week for Lombardy, the epicentre of its coronavirus pandemic, and several other regions with improving contagion statistics.
Neighbouring Slovenia announced it would ease coronavirus restrictions and suspend a six-month-long curfew starting on Monday.
Shaky rollouts
As in India, Europe’s stuttering vaccine rollout faced multiple hurdles on Friday as European Union regulators said they were reviewing side effects of the Johnson & Johnson shot and France further limited its use of the AstraZeneca jab.
France has repeatedly changed the rules on AstraZeneca’s vaccine, first over doubts about its efficacy, then over fears that it could be linked to blood clots.
The World Health Organization said there was “no adequate data” to support switching COVID-19 vaccines between doses.
As for the J&J shot, the European Medicines Agency said four “serious cases” of unusual blood clots had been reported – one of them fatal – with the vaccine, which uses similar technology to the AstraZeneca one.
The US Food and Drug Administration said it had found no causal link between the jab and clots, but noted “a few individuals” in the country had clots and low levels of platelets in the blood after receiving the vaccine, and its investigation was continuing.
Both jabs are approved for use in the EU but the J&J vaccine has not yet been rolled out, and various EU countries have stopped or limited the use of AstraZeneca.
An AstraZeneca spokesman said half of its vaccine shipments to the EU would be delayed this week.
In Brazil, the Senate said it would open an inquiry into the government’s handling of the pandemic, as President Jair Bolsonaro continued to resist lockdown measures even with COVID-19 deaths at new records.
Yet, on Friday, Rio de Janeiro was reversing restrictions in place for two weeks, reopening restaurants and bars, though the city’s famed beaches remained closed.
Follow this link to join our WhatsApp group: Join Now
Be Part of Quality Journalism |
Quality journalism takes a lot of time, money and hard work to produce and despite all the hardships we still do it. Our reporters and editors are working overtime in Kashmir and beyond to cover what you care about, break big stories, and expose injustices that can change lives. Today more people are reading Kashmir Observer than ever, but only a handful are paying while advertising revenues are falling fast. |
| ACT NOW |
| MONTHLY | Rs 100 |  |
| YEARLY | Rs 1000 | |
| LIFETIME | Rs 10000 | |
